Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives. This has been a uniquely difficult issue in the weight-loss ...

The Election Commission's 'Special Intensive Revision' of Bihar's electoral rolls has ignited political debate, differing ...

The majority (over 9.4 million shares) will go to the Gates Foundation. An additional 943,384 shares are being donated to the Susan Thompson Buffett Foundation, named after Buffett’s first wife.

Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...